Evidence map›Paper›PMID 40881716›Full record

ArticleFrontiers in immunology2025

Prognostic significance of systemic immunoinflammatory biomarkers in patients with clear cell renal cell carcinoma: a retrospective multicenter analysis.

Danlei Chen, Zhuorui Zhang, Longsheng Dong, Zhiyuan Feng, Junfeng Yang

Abstract readMulticenter Study
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Danlei ChenDepartment of Urology, The First People's Hospital of Yunnan Province, Kunming, China.
Zhuorui ZhangDepartment of Urology, The First People's Hospital of Yunnan Province, Kunming, China.
Longsheng DongDepartment of Urology, The First People's Hospital of Yunnan Province, Kunming, China.
Zhiyuan FengDepartment of Urology, The First People's Hospital of Yunnan Province, Kunming, China.
Junfeng YangDepartment of Urology, The First People's Hospital of Yunnan Province, Kunming, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: This study aims to investigate the associations between blood laboratory findings, systemic immune-inflammatory factors, ISUP grade, and prognostic outcomes in patients diagnosed with clear cell renal cell carcinoma (ccRCC). Methods: Data were collected from patients diagnosed with ccRCC at the First People's Hospital of Yunnan Province and Xiangya Hospital of Central South University between 2010 and 2022, encompassing pertinent pathological and clinical information. We employed ordered logistic regression analysis to establish the ISUP grading model and conducted association analyses to explore the relationship between ISUP classification and the 2-year survival rate. Results: A total of 1,635 patients were included in the study. Our findings indicate that ISUP grading is significantly correlated with serum albumin levels, blood chloride concentrations, the platelet-to-lymphocyte ratio (PLR), and the systemic inflammation response index (SIRI). The preoperative 2-year survival model demonstrated associations with platelet counts (PLT), albumin levels, blood chloride concentrations, and PLR, AUC (0.776 95%IC 0.710, 0.843). Furthermore, the postoperative 2-year survival model exhibited robust correlations with PLT, albumin levels, blood chloride concentrations, PLR, and ISUP grade, AUC (0.877, 95%IC 0.825, 0.917). Conclusion: This study demonstrated the relationship between systemic immune markers, ISUP classification, and prognosis. It established preoperative models for predicting ISUP classification, as well as models for predicting 2-year survival rates both preoperatively and postoperatively.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellKidney NeoplasmsAdultAgedAged, 80 and overFemaleHumansInflammationMaleMiddle AgedNeoplasm GradingPlatelet CountPrognosisRetrospective StudiesBiomarkers, TumorccRCCISUPLMRNLRPLRSIISIRI

Identifiers

PMID40881716
PMCPMC12380795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.